Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands:The impact of varying the discount rate for health
To estimate the cost-effectiveness of a potential Helicobacter pylori (HP) vaccine for the Dutch situation, we developed a Markov model. Several HP prevalence scenarios were assessed. Additionally, we assessed the impact of the discount rate for health on the outcomes, as this influence can be profound for vaccines. When applying the current discount rate of 1.5% for health, the expected cost-effectiveness of HP vaccination is estimated below the informal Dutch threshold of (sic)20,000/LYG when the HP prevalence is assumed >= 20% in the Dutch population. In conclusion, we showed that HP vac... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2009 |
| Reihe/Periodikum: | de Vries , R , Klok , R M , Brouwers , J R B J & Postma , M J 2009 , ' Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands : The impact of varying the discount rate for health ' , Vaccine , vol. 27 , no. 6 , pp. 846-852 . https://doi.org/10.1016/j.vaccine.2008.11.081 |
| Schlagwörter: | Helicobacter pylori / Cost-effectiveness / Discount rate / ECONOMIC-EVALUATION / TIME PREFERENCE / GASTRIC-CANCER / INFECTION / TRIAL / PREVENTION / CHILDHOOD |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-27210913 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://hdl.handle.net/11370/b9a01ce5-5ce1-4cd0-8610-1d331032b6d7 |
To estimate the cost-effectiveness of a potential Helicobacter pylori (HP) vaccine for the Dutch situation, we developed a Markov model. Several HP prevalence scenarios were assessed. Additionally, we assessed the impact of the discount rate for health on the outcomes, as this influence can be profound for vaccines. When applying the current discount rate of 1.5% for health, the expected cost-effectiveness of HP vaccination is estimated below the informal Dutch threshold of (sic)20,000/LYG when the HP prevalence is assumed >= 20% in the Dutch population. In conclusion, we showed that HP vaccination could possibly be a cost-effective intervention. However, this depends to a large extend on the prevalence of HP in the population. Furthermore, we showed the large impact of the discount rate for health on the cost-effectiveness of a HP vaccination program, illustrative for other vaccination programs. (C) 2008 Elsevier Ltd. All rights reserved.